Suppr超能文献

人细胞色素P450 2D6的底物特异性、抑制剂与调控及其在药物开发中的意义

Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development.

作者信息

Zhou Shu-Feng, Liu Jun-Ping, Lai Xin-Sheng

机构信息

Discipline of Chinese Medicine, School of Health Sciences, RMIT University, Victoria, Australia.

出版信息

Curr Med Chem. 2009;16(21):2661-805. doi: 10.2174/092986709788681985.

Abstract

CYP2D6 accounts for only a small percentage of total hepatic CYPs (<2%), but it metabolizes approximately 25% of clinically used drugs (>100) with significant polymorphisms. A number of drugs acting on the central nervous system and cardiovascular system are substantially metabolized by CYP2D6. The enzyme also utilizes hydroxytryptamines and neurosteroids as endogenous substrates. In addition, CYP2D6 metabolizes procarcinogens and neurotoxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 1,2,3,4-tetrahydroquinoline, and indolealkylamines. Typical CYP2D6 substrates are usually lipophilic bases with a planar hydrophobic aromatic ring and a nitrogen atom which can be protonated at physiological pH, but several atypical substrates such as spirosulfonamide and pactimibe do not contain a basic nitrogen atom. The structure of human CYP2D6 has been recently determined and shows the characteristic CYP fold as observed in other members of the CYP superfamily, with a well-defined active site cavity above the heme group with a volume of approximately 540 A(3). CYP2D6 is largely uninducible by prototypical CYP inducers such as phenobarbital, rifampin and dexamethasone, but it is regulated by hepatocyte nuclear factor-4alpha, a nuclear receptor. CYP2D6 is subject to inhibition by a number of drugs and this may provide an explanation for numerous clinical drug interactions. CYP2D6 has an important role in drug development and it is a common practice for pharmaceutical industry nowadays to a great extent screen drug candidates early in development as possible CYP2D6 substrates and/or inhibitors and drop such candidates where they have alternatives. This candidate selection might eventually lead to a less prominent role of this enzyme in the future for drug metabolism and less interindividual variability in drug exposure and minimize potentially adverse drug interactions. Further studies are warranted to delineate the molecular mechanisms involved in the function and regulation of CYP2D6.

摘要

细胞色素P450 2D6(CYP2D6)仅占肝脏中细胞色素P450总量的一小部分(<2%),但它代谢约25%的临床使用药物(>100种),且具有显著的多态性。许多作用于中枢神经系统和心血管系统的药物主要由CYP2D6代谢。该酶还将羟色胺和神经甾体作为内源性底物。此外,CYP2D6代谢前致癌物和神经毒素,如1-甲基-4-苯基-1,2,3,6-四氢吡啶、1,2,3,4-四氢喹啉和吲哚烷基胺。典型的CYP2D6底物通常是具有平面疏水芳香环和氮原子的亲脂性碱,该氮原子在生理pH值下可被质子化,但一些非典型底物如螺磺酰胺和帕替米贝不含碱性氮原子。人CYP2D6的结构最近已确定,显示出细胞色素P450超家族其他成员中观察到的特征性细胞色素P450折叠,在血红素基团上方有一个明确的活性位点腔,体积约为540 ų。CYP2D6在很大程度上不受典型的细胞色素P450诱导剂如苯巴比妥、利福平及地塞米松的诱导,但受核受体肝细胞核因子-4α的调节。CYP2D6会受到多种药物的抑制,这可能为众多临床药物相互作用提供解释。CYP2D6在药物研发中具有重要作用,如今制药行业的常见做法是在药物研发早期尽可能将候选药物作为CYP2D6底物和/或抑制剂进行筛选,并在有替代方案时放弃此类候选药物。这种候选药物的选择最终可能导致该酶在未来药物代谢中的作用不那么突出,药物暴露的个体间变异性降低,并使潜在的不良药物相互作用最小化。有必要进一步研究以阐明参与CYP2D6功能和调节的分子机制。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验